Proteomics‐Driven Strategies for Proximity‐Inducing Drug Discovery
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.3307512 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Rufeng Fan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, and Cancer Center, School of Medicine, Tong…. Hauptthemen laut MEDLINE: Drug Discovery, Proteomics, Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Strategic Priority Research Program of the Chinese Academy of Sciences, Shanghai QiYuan Innovation Foundation.
Abstract (Originalsprache)
In recent years, proximity‐inducing drugs have emerged as a novel therapeutic modality that induces or stabilizes protein‐protein interactions, especially by recruiting effector proteins to specific target proteins, thereby achieving functions beyond traditional inhibitors. The potential of proximity‐inducing drugs extends beyond targeted protein degradation (TPD), as studies have demonstrated their ability to regulate biological processes such as signal transduction, gene transcription, chromatin regulation, and protein trafficking by modulating protein interaction networks. Rational discovery of proximity‐inducing drugs requires clarifying their effects on protein‐protein interactions, determining drug selectivity, and developing suitable ligands for drug construction. Proteomics has become a central technology in drug discovery, enabling global identification of the direct drug targets and systematic characterization of proteome‐wide downstream responses. This provides a more refined map of drug mechanisms. In parallel, advances in machine learning applied to proteomic data, together with the expansion of proteome‐wide ligandability maps, are further accelerating the discovery and optimization of proximity‐inducing drugs. This review summarizes recent advances of proximity‐inducing drugs, with a particular emphasis on how proteomics facilitates target space expansion, drug efficacy optimization, and ligandability discovery, alongside the emerging contributions of machine learning. Collectively, these insights aim to support the rational development of next‐generation proximity‐inducing drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, and Cancer Center, School of Medicine, Tongji University, Shanghai, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Strategic Priority Research Program of the Chinese Academy of Sciences
- Shanghai QiYuan Innovation Foundation
Zitieren
APA
Fan, R., Ni, J., Zhou, T., Jiang, H., Zhao, W., & Tan, M. (2026). Proteomics‐Driven Strategies for Proximity‐Inducing Drug Discovery. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.3307512
Vancouver
Fan R, Ni J, Zhou T, Jiang H, Zhao W, Tan M. Proteomics‐Driven Strategies for Proximity‐Inducing Drug Discovery. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.3307512
BibTeX
@article{Fan2026,
author = {Fan, Rufeng and Ni, Jiahui and Zhou, Tiantian and Jiang, Haowen and Zhao, Wensi and Tan, Minjia},
title = {Proteomics‐Driven Strategies for Proximity‐Inducing Drug Discovery},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.3307512}
}
EUVIMED